aTyr Pharma, Inc. (LIFE)
Stock Price:
$3.55 USD
-0.04 (-1.11%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $3.65 +0.10 (2.82%) Nov 27, 2:53 PM
Key Info
| Market Cap |
36.16M |
| Revenue (ttm) |
8.55M |
| Net Income (ttm) |
-17.27M |
| Shares Out |
10.19M |
| EPS (ttm) |
-2.32 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$3.55 |
| Previous Close |
$3.59 |
| Change ($) |
-0.04 |
| Change (%) |
-1.11% |
| Day's Open |
3.64 |
| Day's Range |
3.52 - 3.70 |
| Day's Volume |
46,385 |
| 52-Week Range |
2.13 - 7.62 |
More Stats
| Market Cap |
36.16M |
| Enterprise Value |
5.51M |
| Earnings Date (est) |
Jan 1, 1970 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
10.19M |
| Float |
n/a |
| EPS (basic) |
-2.60 |
| EPS (diluted) |
-2.32 |
| FCF / Share |
-1.56 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
68,994 |
| Short Ratio |
1.29 |
| Short % of Float |
n/a |
| Beta |
1.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.23 |
| PB Ratio |
1.14 |
| Revenue |
8.55M |
| Operating Income |
-16.93M |
| Net Income |
-17.27M |
| Free Cash Flow |
-15.04M |
| Net Cash |
30.65M |
| Net Cash / Share |
3.01 |
| Gross Margin |
-159.44% |
| Operating Margin |
-198.14% |
| Profit Margin |
-202.00% |
| FCF Margin |
-176.01% |
| ROA |
-24.79% |
| ROE |
-59.35% |
| ROIC |
-81.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.50*
(280.28% upside)
Low
12.0
Current: $3.55
High
15.0
Target: 13.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 0.42 | - | - | - | - | - | - |
| Gross Profit | 0.42 | - | - | - | - | - | - |
| Operating Income | -22.98 | -32.82 | -47.15 | -57.94 | -47.62 | -23.55 | -19.54 |
| Net Income | -23.60 | -34.52 | -48.21 | -57.86 | -47.97 | -24.35 | -20.01 |
| Shares Outstanding | 3.36 | 2.14 | 1.85 | 1.69 | 1.13 | 0.06 | 0.05 |
| Earnings Per Share | -7.03 | -16.11 | -26.13 | -34.16 | -42.42 | -415.65 | -397.45 |
| Operating Cash Flow | -20.01 | -31.06 | -42.36 | -52.86 | -36.80 | -22.82 | -17.31 |
| Capital Expenditures | -0.03 | -0.59 | -1.31 | -0.60 | -0.66 | -0.25 | -0.64 |
| Free Cash Flow | -20.04 | -31.66 | -43.68 | -53.46 | -37.46 | -23.07 | -17.96 |
| Cash & Equivalents | 31.14 | 49.55 | 85.12 | 72.15 | 95.54 | 15.85 | 36.46 |
| Total Debt | 11.73 | 16.03 | 19.73 | 9.54 | 5.14 | 10.28 | 6.89 |
| Net Cash / Debt | 19.41 | 33.52 | 65.39 | 62.61 | 90.39 | 5.58 | 29.57 |
| Assets | 36.19 | 52.75 | 89.36 | 80.52 | 130 | 20.64 | 39.79 |
| Liabilities | 15.16 | 19.10 | 25.11 | 17.72 | 14.63 | 112 | 106 |
| Book Value | 21.19 | 33.65 | 64.25 | 62.80 | 115 | -91.01 | -68.50 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
aTyr Pharma, Inc. |
| Country |
United States |
| Employees |
39 |
| CEO |
Sanjay S. Shukla |
Stock Information
| Ticker Symbol |
LIFE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LIFE |
| IPO Date |
May 7, 2015 |
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Company for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.